ARTICLE | Company News
Crucell, GenVec deal
August 19, 2002 7:00 AM UTC
GNVC received a non-exclusive worldwide license from CRXL to use the PER.C6 cell line in the development of GNVC's lead cardiovascular product candidate BioBypass angiogen. CRXL will receive an upfron...